0001104659-23-092871.txt : 20230817 0001104659-23-092871.hdr.sgml : 20230817 20230817091851 ACCESSION NUMBER: 0001104659-23-092871 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230817 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230817 DATE AS OF CHANGE: 20230817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nuvectis Pharma, Inc. CENTRAL INDEX KEY: 0001875558 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 862405608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41264 FILM NUMBER: 231179947 BUSINESS ADDRESS: STREET 1: 1 BRIDGE PLAZA, SUITE 275 CITY: FORT LEE STATE: NJ ZIP: 07024 BUSINESS PHONE: 360-837-7232 MAIL ADDRESS: STREET 1: 1 BRIDGE PLAZA, SUITE 275 CITY: FORT LEE STATE: NJ ZIP: 07024 8-K 1 tm2323981d1_8k.htm FORM 8-K
0001875558 false 0001875558 2023-08-17 2023-08-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

  

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 17, 2023

 

Nuvectis Pharma, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware
(State or Other Jurisdiction
of Incorporation)		   001-41264
(Commission File Number)		   86-2405608
(IRS Employer Identification No.)

 

1 Bridge Plaza Suite 275

Fort Lee, NJ 07024

(Address of Principal Executive Offices)

 

(201) 614-3150

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of Class Trading Symbol(s) Exchange Name
Common Stock          NVCT Nasdaq Capital Market

 

¨ Written communications pursuant to Rule 425 under the Securities Act.
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
   
¨ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 8.01.Other Events.

 

On August 17, 2023, Nuvectis Pharma, Inc. (the “Company”) issued a press release announcing that NXP800 was granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of cholangiocarcinoma.

 

A copy of the Company’s press release is being furnished as Exhibit 99.1.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits  

 

Exhibit    
Number   Description 
99.1   Press release issued by Nuvectis Pharma, Inc., dated August 17, 2023.
     
104   Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  Nuvectis Pharma, Inc.
  (Registrant)
     
Date: August 17, 2023    
  By: /s/ Ron Bentsur
    Ron Bentsur
    Chairman, Chief Executive Officer and President

 

 

 EX-99.1 2 tm2323981d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

 

August 17, 2023, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration (“FDA”) for the treatment of cholangiocarcinoma.

 

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "We are pleased to have received this designation from the FDA for NXP800, which emphasizes the need for new, innovative therapies for the treatment of cholangiocarcinoma, a deadly malignancy with only limited treatment options available. NXP800 is an oral small molecule with a novel mechanism of action that has demonstrated robust activity in several preclinical cancer models, including ARID1a-mutated ovarian, endometrial and gastric carcinomas, as well as cholangiocarcinoma. The clinical activity of NXP800 is currently being evaluated in a Phase 1b clinical trial in patients with ARID1a-mutated ovarian carcinoma, with additional diseases planned for clinical investigations. This orphan drug designation is an important milestone in our journey toward our mission of developing NXP800 for the treatment of serious conditions of unmet medical need in oncology.”

 

About Orphan Drug Designation

 

Orphan Drug Designation is granted by the FDA to drugs or biologics intended to treat a rare disease or condition, defined as one that affects fewer than 200,000 people in the United States. Orphan Drug Designation provides certain financial incentives to support clinical development, and the potential for up to seven years of marketing exclusivity for the product for the designated orphan indication in the United States if the product is approved for its designated indication.

 

About Cholangiocarcinoma

 

Cholangiocarcinoma is a cancer of the biliary tract originating in the epithelium of the biliary tree accounting for approximately 3% of all gastrointestinal malignancies, with an annual incidence of approximately 8,000 – 10,000 in the United States. Surgical resection is the only potentially curative treatment for cholangiocarcinoma, but the disease is often diagnosed as unresectable because of local extension and/or metastases. While several targeted therapies have been approved in recent years for subsets of patients with cholangiocarcinoma based on specific tumor genetics, the overall prognosis remains poor with 5-year survival rates of 20-50% after resection and almost 0% in unresectable tumors.

 

 

 

 

 

About Nuvectis Pharma, Inc.

 

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule currently in a Phase 1b clinical trial investigating the activity of NXP800 as a potential treatment for platinum resistant, ARID1a-mutated ovarian carcinoma. The FDA granted Fast track designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor. The NXP900 IND has been cleared by the FDA and a Phase 1a dose escalation study is pending commencement.

 

Forward Looking Statements

 

This press release contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," "set to," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nuvectis Pharma, Inc.'s current expectations, estimates, and projections about future events and trends that we believe may affect our business, financial condition, results and timing of operations, including clinical trials, prospects, business strategy, and financial needs. The outcome of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict and include statements regarding the preclinical data generated to date for NXP800 and NXP900, the Phase 1a data generated and the Phase 1b clinical expectations for NXP800, including the safety, tolerability and other observations from the NXP800 Phase 1a study and timing, and safety, tolerability and efficacy data from the NXP800 Phase 1b study, including statements regarding NXP800's potential ability to become a therapeutic option for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma and potentially other cancer indications, including cholangiocarcinoma, and the timing for the commencement of the Phase 1a study for NXP900. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are subject to market and other conditions and described more fully in the section titled "Risk Factors" in our 2022 Form 10-K filed with the Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

 

 

 

 

 

Company Contact

 

Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
rbentsur@nuvectis.com

 

Media Relations Contact

 

Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com

 

 

 

 EX-101.SCH 3 nvct-20230817.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nvct-20230817_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nvct-20230817_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2323981d1_ex99-1img01.jpg GRAPHIC begin 644 tm2323981d1_ex99-1img01.jpg M_]C_X 02D9)1@ ! 0$ R #( #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" != +,# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBJ@)QC M=+P6R69LX..1TXZ[0>F"1SQ6=J.HV>F65UJ&H7T6GV-G;S75W=W=Y';VMI:6 MP#37%Q<2$)%;I&-UQ,S9B4EE(/SA)3E*G&$)3G.I[/DBN:2EUBE%252K"C"I4KRA1IT:$?"LT/EV-SA2L6O:],DNG:0QYWVL8U#54P&7 M3G1MU?E[^V[_ ,%-_$?C._UGX7_L^:O>>'?!L(DTS5O'5H9+'Q%XKXENY6EGF-S-/(0%8N99;@%WT7)YGA/LSA_ M:&2RQ:=I4>$\J]VGFN'C=J.;X^5#+JLJ>(>'A75*$\5^Q_CK_@LO\8-6FDA\ M!> / _@NSF3;!<:V-8\7ZLKC&Z2VF:X\/:4_LL^EOCH=Q&X?)_B7_@H]^V!X M@N2__"Y-2AA8<6FE>'O".E1+]/[*TF#4>,]1/U]NOBWPL_99^/7QG:.7X:_# M'Q3XATR\2*2+75TY]+T&9?XT_P"$DUE(?#DA4$;[8:I]O!(+3#I7W)H?_!(+ M]I35K>&;5=1^&GA8O&'DM=3\6ZI=ZBC_ -SR=&\,ZMIJJ.,A=68C^YD&\/LOQ<(I.RW%>-_$F7SE?_A'PV*XW/>*2^?K# M_@H]^V5I\RO_ ,+JU9HP<-'?>'O!=TK?4W_A>9A]0?8U]*> ?^"P?QZ\./!; M>/?#O@?XA:2H.YV@O?"WB*Y;'!_MC3731HP,]$\*J21U!Y%35/\ @CS^T=9P MR2Z9XB^%6MLH^:&#Q5K]G=OZ>6M[X.AMN/0ZBG//(-?%OQ8_8\_:*^!\-QJ' MQ!^&6O:=HD'G/+XBT^&VU_0+>WS\LMSJV@3ZA:V@'16U26R(., \T4,)]'3C MJ;P6 H^'&.Q4[I+#UZ>1SG9.[I2K_P"K]7FBG=.+.*#0?&$]FFFZC=2$!(-&\3P*NE74CGY(+2_&G:I?,S?V?I M\ZH7'Z!B9I$0I(")$5U>-1(&#$>63AI%93SF1'Y8$'[O'\'0:2TWPM*\4T3R M$"+>K+.@$-TLHR"=LOS$-D;CD@'FOU;_ &)/^"D7BWX/W>E?#GXQZGJ'BSX7 MW$@M+75[N674/$/@1),BWNK63S7.I>&;5@T'<\3B:F#5:I7X2Q4I5U2'5M"UFQM=1TO5 M[*;[58ZG9W<"7%M(QX,C1M&S J-W><8'FDJS#J^"0C,!\Q M+;2>,D\G&.@K^-Y*<)U(3ISIRI5JV'JQJQ=*=.K1FZ3C*G449IRK)TTFDTTV M]#_5W#XG#XNC3Q&%KT<3AJU.C6HXC#U(UJ-2CB80J8:M&I3E.$J=>E5HU:-2 MG*K3G2J*<:KC&1>HHHI&P4444 %%%% !1110 4444 %%%% %%@05))R"NX[0 M04)(96)(^4\,3U0 ^M?SW?\ !4G]LV?6M7O_ -FSX:ZR]OH>DN+3XFZSIUR0 MFK:U((X8_"+36\H']D:27F76"&F6\U7SK.[^P6^B,-6_7_\ :U^-[N;J:2YNKJZN)#)<7-Q<3%YIKB>1F>6:5 MY))'R[LQ.:_J[Z+OAQA,_P SQG'>;818O#9#)4\APE:">&QV?PP]#$K'58RB MZ=1Y=1Q6"E0IRBX2KXJ,9I^PG;_,O]H?X]YEP=D&4^#7"68U,'G'&&%6/XJQ M6%KNEF. X:GBI8;+LOIUHRA.C3XCQ=/%K%S4XS>68"O@)+ZGFF)D7?#'AS7? M%^O:7X=\.Z5?ZSK>OWMKINE:?I]LUS7MU%9V=M;+'DB>6:Y186FQ;PQE M[VZ*"VWK_2)^R!_P3"\!_#"TL?''QQTK2_'7Q"N(XKN'PQ=*FI>#?"$K#:UK M)!Y36OB/6AEDO;FZ232+9]D.GP7KQKK,_&_\$I_V3;#PEX4B_:,\::7%-XG\ M5075I\/8+ZW4OH/AJYEEM[KQ!"DX+0ZEXG99+6WO(T%S'H4:>1*+?7-123]G MPD8=]L*H%(5,!55EP6 '&T1IDM@?*&.< FNWQ\\)K*HL5F$U4YYT:45&?D_0I^A] MPY@>'5\/Y752JX'.LQP%:-2CC,XS+"]JCWDU[2_SE*+OW=]=#_46%&G3C3C",:2IV48TH1A1BDK)4\.N6E22 MZ*E&FETL4\L(P"%7UW1L1S_=!#'_ +Z ![4U[:.>%X9H8IXW!#12QPM&ZMPP M>,QM'C&05<-D'!XP!>"JHPJJ .0 #ZX HV(,X5>>ORCGZ\ M\:DN71W6DKM6[JWZE2IQG&<9^_S*S4DG2:MJG0?-2L^TXUEWN?DC^US_ ,$R M?AI\7=.O_%OP=L=-^'?Q+CMYKM=(L+9-.\&^*)V!E-K<6,=LD.@:G=/CR[^S M3[+>.9!J>GRLZWUE_//?_!+XB:;K7B[PI?>&]4L_&/@ RR>(?"DMK(FO6&GV MD+37^I6UIL/VS3]*M1:7][J4(N8'T6ZBU>UB:P^TW8_MZ\N(!0%) 55 )+*0 M , XQC/(&1@G&1BOC3]I+]F:R^*L^@_$WP!J=MX'^/GPZE;4/ 7C>*6>WCO# M:S"<>&_%TL'D76HZ!J$);[5/$G[/?B35K.[ MT.WTNZ\7>$+:_N_L^L:-=MJD:>(-'TZV;/VC2[R2X2]ELU,/]FWXN]0LDU"2 M_P!7FT_]\5^;'.!CC'!P<@D9)XQC&3U QU.?YSOVCOAMK7[-7Q1^"'[:G@CP M3>?#S2_$OB/2;_XC?#>WMXDN?!7CR>*\_P"$I\-02V<<4">'_%&F+K>G6$L& M;!Y(]4N-,:WT_5=(M$_H7TR_@U/3=/U/3&BN;#4K&&_LKN)]\5Q;7EM%<^'7%%"ICN#/RVG@ZDZU?*:> M#678^I] ,@_B! M\(/ ]U\3?B?X%\!6:3B;Q?XMT#07DA03FV_MC4[/3I;K# YCLC,]W)OAMXX\7_#_ ,1_\+J^%-@NO>"? M$NM>%-:&GW=UK375F-5T&]L+X6ER4C:YMQ.(;CRHS(C[4Q_*W^T3_P %0_VI M/$/[&/[.G[(WQB\>_&GX8?M<_LZ_'/PLFI^)],\7^+-"USXK?L[>-?AD^M_# MGQ#XM\9Z#JME)XBUC2K#6]$B>[N+B]B\3>%M0\(^+KF76->O]6U=/X8X>X!S M7BC!83,\'CL.I8O.L1@,9"O"M4K4*6&PSQ>,Q\Y*I&-:71)?Z4M%?@WJ?_!7KQIIW[8O_!2;]EV/X+^'I]*_80_9,^(/[1_A_P 8 MR^-]5COOB/K'@GP5\,_%UIX5U;3AH1L="L=8G\=W%A=ZC8:A>W6GKIJK'INZ MXR? _AE_P7>^)GB+PI_P38^+GQ$_9W\&>$/@C^WC\4?'?P9\4^-;#X@Z[=CX M,>.O"?Q:U3X:Z4FH3:CX9TVQNM-\2:?<^&_$]O/JDNE""QM?%TIO*MEV&J5XJG=WM3UGOZ\N*\EC. MK3]O6:DVEVEQ;:W'KJ>'_[%W:IO+@CB:-&=5Y:W*&( M^J+#QK4I8JKB8/#PK4MB:="MR./+4NK-+3&'&?#TZM.E]=Y54O: MNZ<_JRYO>HWKVY/]HH_OZ=H_P]W<_I9VMA6VB_$/X=?&32_$WCSX:>%(]9&C)X_\ '&@:S#HZW.B6[)<7 MPLDTOP]J.K:387]YH\=Y?G3M+U7X4_8Y_;E_X*,?%O\ X*K?MT_#3XP>#KS5 M_A;\.O!GC[PK\0/A]I_QATS3/#_[+?@S0])U74O#NO\ @.QT9(8?''BSQ7K- MGHFAS^(+'1+SQ7!%KXU.;4AI.G"!-(<'YE_PHJIB,HB\KPT<4^7-,'B'4MBX MX2KAZ([".#5O#E\XW12YAUBQTZ2:,21;XVD1F$;L:R/V2M7N=4_9H^!\E M\TLMW#\,_".G7$MS')%-))I>D6.ER^>CM&T-RWV=EE5F7%P';:Q!4_RN_LM_ M\%@-6_9-_P""5_@OXW^#?@U\0_',WQ*_;*\9_!Y]>_:$^/GCGXL>$_AH%\'^ M!M0?Q+X]^)6%[]$?%/_@HK MX[_:H_X)3?MF>))X?@]\/=0^#_Q$_9L\.0>,_P!C']H6Y\9-K_A#Q7^TG\.M M.UZ]TOPWX8A\-_&KX6W>K: -2ATO3?$&F:?K?CC3=:GM=-LX+ZVUK1[;W*^0 M<0TD\DQV)> ES8E+%U:>5TZG)45Y9?"4 MVZK4G\/1CP_+C;#^(F$A5PV98OP]K9%G&!AA:GM\?AJ&94^)TB_8?\)4 M\3G]6'M(RE4IYMRJ2IPG$_JQWGL&.3E#9_ 4GPYLGU+2 MQ_:KZY OA_KOP+_ &IKG0/@#X3^ M),GQC\;>*OVC%^(>H^"_B#XQ\*>/OB)I6M^$[;PA?Z!\0;7X>ZZZZ'I/C?4_ M$OA6TO="N+R]UJ^EO='TSYC$<.5Z.&GB88FA)T^7FH8B,L%6YI+,9\EJE7$P MYU0RYXCEYTW3KT^5WC+G_0:/$>'JXB&'EAJZYTVJF'E3Q=-)1R]7?)'#NWM\ MP6'O9VG0JR?NR@E_2)17X()_P5J^)NA?M'?"/X7^/=!_9*L]*^+G[1EE^SK< M_ KP!^TO'\3_ -K?X/R^)?$6L^&/"?Q ^*^D^"]%UGX4V%O<7NF:9J/B?P59 M>-X=5\*Z;XHL+&'7-*K+XF_%/XA6W[6]A^S6/$-X+KX#M4^W7KV)=&D633&\,:E8ZA'BN&\TYX4Y+!QE.KAJ,5+&P2=;$SG"G13EAHISY MH-.2_<6]Y8EQ]XWAQ!@*D)SA#&R5-W?+A&VZ5D_;K_:/X>JW][R1^^-%?@EX MW_X*'_\ !0?X?']LCP]JO[.G[*VK>*/V"OAWX=^/OQQUW3/CA\3K;P9XU^$? MB?P#XB^(6E>$OA1:7OPFD\41?$Q-(\"^.(=3U3Q=9V?A2"XTS13!;R#Q%C2- M[]K;_@J;\3?@='<>)O">E_LD>!?!%A\#/!OQO\-Z3^TS^TDGAKXQ?M")XK\( MZAXRN_!OP4^$OPXT;QIXOTA_#D-E#X6N?&7CS3+/3-:\9ZG#IGA_0[W2M-N] M;FSAD&8U:M*E3E@:CJ[.&.A)+F6'='F4ZLK?4X[:>:(!99XW< BOP_\6_M@_%/ M]F/]HG_@KWX\T'0]2^-5[X2_:0_X)M_##X;_ E\4?$74O#7ARSD^.OPO^$O M@>]LO#=]>P:_I_@J*_UGQQ+KEY=P:-#IM_JB->W4%Q,9'?FP&5XO,:F*HX:" M=?#+#VI2TE6EB#_P!FWQI\+='^ /Q)\0:IX)^+S_M7_%SQ%\"OA7X+OM9^(7@S M0=5\'ZUI_P 4M#71_$^L/I>KVTWAV:X\4:;HEOY%IH^H_;?[._CW]L:_\9^, M? _[5GP9^%_A:#3_ [X?\3>"OBU\"OB+J7B[X:^)9M8NM5LM;^'.I:#XZT; MPC\0M"\=^$GTN#5VU8>']4\'>(?#>LZ?+;:II&M6NI:0[Q&58K#4?;UI8>-) MV<)K$0:KKEH2_P W\*3VL?95%%%>:>F?SO?\%I?#+P>-?@[XSCADDM]8\*>( M] EG )CMI/#FJ6NHK!(Q&!)?P^)2T"DY*V4N!A37YV_L,^,K3P'^U9\%->O_ M )(!XQM=%V,VU%7Q=;W?A0/-)G_5P1:Y(9]S ?(-W K]^O\ @J/\'9?B=^S/ MJ?B#2H&GU?X8:O9^-DB@3=//H!@FTKQ$H,7SQ6ME8W@\0NREI&314A(7D+_+ M-8ZE>:3JEEJ-I+/9W6GW<5Q:SP.\%Q:RQ2K/!.5$F6:)ED61%D# M!U!7_1OP&Q5#C7P2J<+NM&,L'@<]X2S&32G]4HYE5Q6*P3G2BU.49X3'PJ)O ME4G0K0;7LY6_P5^F5E>;>%GTMY\?4L'*>%S#&<'>(V5NFU1AC*^01RNGF.&I M5ZZ]C+&4\WR:HJU&+2I!).3 M\&?MJ_\ ! S]G+]LRV_9JU+5/B)XO^&7Q%_9Y^%GA+X0W7Q'\)Z#X;O-2^*/ MA/P+I6D6'A5O&>DZF6M/[4\/W&FWESIE]IS+,(?$%WHNI'5=,M-(@TG]8OV7 M_C39?M!_!3P7\2(;B$:IJ>G6]EXILX)8\Z9XLTQ(;?7;$VHED>UBEN5DO+%9 M#&\NDW6GWB1K]IY^@'#*G[H*XQ*ZJ7VJ#L)1 <@!0P;." %!+=J_@6IF'%/" M^.Q&22KU\KQN18K,:-3!II2H8^O1C@\TA7:@HU;SPV&Y)IRA7HT_;4'RSA(_ MVYRR?"7'.1Y5Q3@%1S3*>)((?"/A:X\6^"-4TW7K#6Y=.NWM[[23? M6C:5U^I?\$/_ ()Z[_P3*\,_\$TM?^)WBW5O#G@CQU?_ !(\%?&&30M"A\7^ M'/%5]XZ\0^+7U&ST9)?[,;=HWB;Q'X/:-KP-)HVKWLN\2QQHO[C;$_N+TQ]T M=/3ITH*(>J*>0W*@_,&W ].H;Y@>H;GK4?ZT\0JC@:"S.HJ67/!/!15##)X9 MY?3Q&'PCIR]ES2=+"8AX7][*:E0O3E>')&/IOAG(W5Q=?^SX>UQRQ:Q+]M7Y M9+'3PU?$J,?:6CSXG#K$QLERUK35FY'XA?$3_@AU^S%X^_8-^!/[#B>)_&?A M1/V<]=_X37X9_&KP]#HT?CJW^(^I:EJ6L>)/%&LV-Q;2:5J=AXKU?5KR;5/# M\I$?D6N@Q:=J<#:)921=O\)O^"3]EIGAWX^:!^T_^U)\7/VL[+]H#X\!?"?P/X>\.:U#9+>ZOX/\$?#K0UMM!\:PFPL;^R\0Z??6Z6^I127 MD6FI=:G=S2?L*(XQC$:#;P,(O ( ''& 2..Q(Z$T>7&!M"(%QC&U<8SG&,8 MQDD_4U'^M'$CHUZ+S6MR5L74Q\HJ3N\7B)X?$8FJJ_+]8H>TQ=!58K#3BDE% M2C=2BZ7#F3*K2K?V?AO:4U3M/DT?U>G]7PW[G_=W[/"WIRO"\I>\KIMG\_7P M'_X(6?\ "H/$WP/T_P 0?M^?M:_$7]GS]F[Q->>)?A+^SW+K-IX(\/V,LVK1 M:\NC^*O$7A.]M;SQ)H8U"!!=:=9:7H5F+.;4=$TB'1=,OKNUD]JTG_@D-HWA M+]OGXP_MP?#O]ICXH^"K+X^V&MV7QC^!=GH>BW_@_P :IKW@V[\,SV^IZQ-> M0WCZ/9:MWU>.Q(ME_8]HD4*%1&SA7W AXQBHSY:%S(JDQ %@H) C4C9E>!O#8(*]",YR*JOQ3Q'BJN)JU\RC-8G MSPM6FL%E='EIXC%_6\1"K'#8"%.+JS47]%^KN4FL7>,6KN%*SPLHZ*ES:GX1?#?_@B!;?!O]D30?V6 M/A!^VY^T=\-)_#?QE\3_ !AA\>>$HO#MC8^(Y_$ND^#].NO!7Q'^&Y6Z\*_$ M#PM9S>#],UFRT_6'AN(M2FU.."5-)U"ZL)J/PS_X(5?"OP-\._VH?".M_'GQ MQXP^+W[57B/X*^+OB9\5=(\ _#;X=:3I=E\'/B]X7^+6DZ+X.^$/@O2=,\$> M%[?Q/KWA(VNJ-")4CM6Q!P0:WCQ-Q-.ABG5S'W)8R..E'ZMA85*F-JXU8ZDI8KV*K2JU,3 M3]NVYRA3C!1:Y$H+DGD&08?%8.,,%&%2I>A253%UH*6$A@HY?4JQ@ZDG[&E1 MK4,/4EHHUL50N^:>G8W=HM[975FTA1;FTN+9WW$L!<1F-06QR &) 7TQ@<"O MSM\'_P#!.WPAX-^!W[!OP/M?B3XHN=-_8+^)_@KXF^%_$4^D:-%>^/)_!?@; MXB^"+?2/$=LLBQZ797UC\1;N^N+K36:?SM&@8AS,''Z2;5_NKV[#MT[=NWIV MH\M./D3CI\HXXV\<%0Q6)PT90P]:=&,I<]H-Z2]G5P[E[WM-7A: M]>EMO4;V/>KX+#XITY8BC2K2@K7G%ZI3A75N1TVK8FE1J?X8);GXC_#[_@CV M_P /]"^ WPSA_:S\=3_ _P#9D_:$\ ?M"_!OX;Z?\)OA3X9O+S5_ WCC4?%E MOHWQE\;3-9US0H=?#^%M2-]JG_"4ZS::]K-A:2K]-2?\ !/+P M9+^SK:?LZ_\ "Q?$JZ1:_M9R_M:1^(DTO2QJ;^(9/VK+S]JM_"360E%H-,.M MW1\,->G_ $HZ83J15KQR!^CHBC!)$: D8)"*"00H(.!R"$4<]E4=AA=J]-JX MZ8P.GITKT*N?YU6J1JRS&NIQQF&Q[DO9W>*P\Y5%-KV26LYRE_*[ZT+6BN*C MP_E%"-2%/ T$JD/J_P#R\TPK27LOXK]ZRMS*RV\[_GYX]_8-\+>/-6_X* ZM M>_$/Q':2?M^?!#P7\$?%=K;:;I\,N\?F:KJEY;?$R MZUB6WUH26RS:/86\8\JXFQ\X>(_^"4$\_BGXO:I\/_VI?&WPT\*_M(_!WX;_ M :^/6F:3\*_A7KOC_Q%I/PR^#=C\#H)_AQ\5O$FC7>J_"RR\2>!-'M/^$@T MNRT+Q':1:NU_XA\)'PWJ^H7%U)^R6Q/[J]0?NCJ,8/3J,#'T'I1L3.=BYYYV MC/.,\X[X&?H/2L:.<9KAY0E1QU:+BJ2W@T_JRP2PJ:]C9JDLNP::=[JE[_UB M[O=7(\KKJI&K@Z,HS]IHE437UA8SZSK[7>I]?Q7+;X?:*][:?!OP#^!GQO\ M@AX]^$G@2U^*-QXF_9;^#O[&/PY^!UGH.JZ5X6L[_P 4_&WP1KUKI-O\30ND M:.FO:7>W'P\T5=.\36-SKI\)MJ.H:2?#WA^WU&TUB[E\T^(__!-7P;\1O&?[ M4GC6[^)_BG3+G]J/X[?L=?'/6;"VT?1YK?PKJW['DGP\D\,Z-I#R/YE[8>+F M^'5@^N7-[BXLS=2FV#A"9/T\\J/.?+3.%7.Q<[5SM7..B[FVCH,G&,FEV(,X M1>>ORCGKUX]S^9J*>:8^EB%B:-6%"L_J[J3I1Y7-X>NL:I6M;F^OTZ5=-JW+ M32DFTD;O+,'.A]7JTW6I15H1JOF.?&VCR?'KX*?!#X2"+PG6GAGX%_ M8]7^&&I>-/'=Q);36O$5UHE_:Z=X;C\.V&A6-NGZ6A$485%49! MP% &0 < =0 /8"@*HZ*HXQP ./3ITY/YTUFF81I>P6(C.C9)PJX?#U&URX M2+492IR]@I+ X535#EYU3M*]WS0\IP4JD:[HN%>*]V='$8B$8O\ VRS:4U[> MSQ^):^L.:WF1XIHV:.1&5R#_'C^V9^S;KO[,_QFUCPI+9W M4W@_493JO@#6I5N+B'5/#5U<2FTM#?D&&75M"=3I^MQ7!2>6XM3(D8M=3T[[ M;_8^P.P;<@[2%); SP!GD?, , D\<<@ 5\]?M%?L_P#@W]I'X;:S\/\ QK$J M)=8GT778XDGU+POKMO#< M0I4I0Q=3FCAL9A\-6E^ZGB;_ ,XG_!/K]LN?]F3Q_+X>\73W,WPC\>W$"^)5 M7?,WAK50\<&F^,+:%W>(O:6I,&N1PJESJ>F10R&35;[1]/TU/ZHM(UO3_$>G M:?K6A:A9:KHVJVEIJ.G:AIUTEU9WVGW<*S07EO+ [PSPS12(T+QN(FW&25<; M:_C5_:+_ &7OBC^S-XJ?PY\0-&G72I[F>7P[XDLC]H\-^(+.TD4O>Z;>QH42 M59?+;4=/N6&N:>S02W-I#'=Z4]Y[G^R-^WG\5/V:!;^'+N"X\I7$T3:0DLQ%_>>&=3#;-.N;MB;JYL4DO-,N)"]N\2WD\VLM_2GB[X-8#Q,P MU/Q#\.L5E^-S'$T8^VC3KT:>#XAP^'CR8?$TL9[:%.CFU&BOJT\/BT?\ _1>^E5GGT>L?C/!3QMROB+*^%,KQM2C@L9CQ7M)8B,L)6J0P4YU\5ED\5@L6Z6&_K@HKXW^"G[>6#X/\7ZC:^'_%"3R!B]M!:S72V>L& ;Y?#VJ:M"K-G MSF P?K&.X\R R13K(C@-$\!Q].%*2;4L13H8N>-PCTLZ>*R[#UD]Z*->BL\S[(PT MCE6(XW,8P?\ OJ3(/3T[\]JP];\3Z!X8T>\UGQ+K^F>'](LH?.O=7UG4H-,T MZS08W//?7EPEO"BD@,_FLHW#=C(->;252O4I4\/1KUW5ERQ5.C4E)R>T*=*, M)UJ]63]V-'#TJLV]$V[)_0U\11PE"KB\76HX7"4:;K5<5B*T*&&I4E9NI4Q& M)>%PU."3UE5Q-*W8W(P=F"RL JE0S?.<@DN^#D%ARBD\C';FOG[XQ_'W0?A9 M<>'_ G8PR^+OBOX[FN+/X??#K3"SZQX@NH89)Y;N]-L)%T3PU:0Q22ZEX@O MV6TTVRCN;V99I+-H'\"\7_MJZ?XLUA_AU^R;X?;X[?$NZBC$FLVDDUE\+?!L M,F^.UUCQ;XON88[>]LV9=]E!H[2?VL5EABOXW3[))@^#/!MM\ M8NO$/BF[; M]H;]M+XN: MK:_=:)X?E^YPO!F)RR4,5Q)@L1AL17@\7EO#]2I3HYIF-LP@_:9/EV24<\RC+*,:V+SG'36&KX*G]'067B/0? M#&C?#9O$4VL_%+Q[/>:GXO\ $=O-]:?I5KHEAI^D:7%'8:9I5M#9V5I$I:.&RLK984@ M&,[5A1%51@E%& 2.OEOPB^&=SX#L]7U[Q5K2>*/B1XRNK34/&WBD6\UK#<36 M4/D:9X?T2UN)+B72/"'ABT#:;H.D2322(K7NIZE)(G0H5(UJ6'G*M5K0I\E*MB*B?/4ITY1THT8^YA8R M2E&/OR2E.T/TOAG+<11P>'QV.H5\'7="GEV"PF*KO&UL'E-'F4*5>M.\:N8X MYU*F-S3$4W[.ICY4'2_<82DBQ1117FGU@4444 %%%% !1110 4444 %%%% % M)V)4!5$DHV;ES@ '&#@'DC@>W<#-.(!)R!PO8J6(7DC'.X*>GICC@&K/EIDM ML3<>K;1D_4XR:-B6+4;N/,KM-VT=[JRMI9)V> MMV0X:_'.<7&E%PJ/W8N'\2I3<+3C4J=W*W?J>8?$CX:>!OB[X2O?!'Q#\.:9 MXH\.:E$3+IVIV[R-#*%;[+J-AV,UO=V[-F&X5,U^,OQ-_X M)M?$;X5WM_J/P1C\/?&_X;7PN;S4O@M\1@+;4X/M$5S$TOAS5[;4= AMM4BC MNYA;ZQHVI^$M7MTM-*C2#4_(OVN?WH,:'JB''3*@_P Q08XR,%$(&< JN!GK MV[]Z^YX/\1^*N"(SPV38U5LHQ#YL=P]F,\16R;&54K*O[*E7HXS!8Q+W8YCE M^.PN-@K-RQ#44OQ?Q8^C_P"&_C$L'B^*,KJ83B3*L/[+).,%?B3X1U/QCX/NKHN8TM?#?B?1K#3/%*:*TY#O?7GA'Q%";?(&HA&VC MN/!?P]^.O@N/3S\*OVP?A4(UXM[#PW^TA<>%711C='?^&O$K^&)AD\[)- E7 MGY2W;^I/5?"_AKQ#ISZ5K_A[0];TN57273=7TC3]2L)4<%722SO;>:W=67 9 M7C8,!@C&*^>?$/['/[,6MS>==?!3P#:OQG^Q=$B\.H2?^F6@/IL?;^[GWK]Q MPOTBJ>-I4Z&<9?F=Z:C&6&QF&X7XXP;25I*C6XMP6!S&A1FXQ?U6?UNDFN9U MG+0_C;'_ $$<=DN+EC^&^)(/A%FE2HFVJ^-P/AEF..R/&XN" MD^7&3Q%&;^%X>$#\W?AOX#_;B^(&G31ZG^W5\/=%\HM]JTO0/%'ASQ=KEI:Q M_P"IO[F7P]96LRF<\F*/6PI PS>NI-^R[^S?%K5G=?M+?M=>+?V@_%=NX-KX M+A\57=_?74SDEH=+\%Z!K/C7Q\T6>=FB7EE$O5XB6P?OG2_V(/V5K&43_P#" MEO!M^R839K5E/KL+JF-JO!K5S?PNJ_PJT9 /UKZ#\+_#GX>^"+,6?@SP)X.\ M(VBMN%MX8\,Z)H$&XXRWE:58VD8)XR0N>!S7Q6;^+*CB,16X=KX[)IUDH6R3 MA3P^X6Q#@VG*G+,\MP>:9C2=K2Y#5KMM7P^:8/&X/2\8K52^5_ V@^,? M^$/JSJ0S:Y M\1]2T^^M;D^;=^%]>5G ]X^'OPD\*_#F'4)-+@U'5O$'B"1)O%OC3Q'J)U?Q M;XKNH5EBCFUW6&56>WMXW(T[1K&UT[0=!BDEAT6SLHB8F]E"(!@*H'H% ''( MZ#UHVK_=7\A_A7Y%F&>XW'O%Q48X6ACI^TQE..*QN+Q6,J:M5,RS7&5)YCFM M1-W4L55H4TUS+#QE[.6'_J+A_@/)\B^H59J&98S+*%*AEE2I@'\IH8+)N&Z59QC.2RW#SQ"E&RQRIUL71Q;-B<%44G&,C@@#.!Z@#D@<> MW6G-GL%QC!/'!Z8Y]N/QIV .@ _"C Z8&/3%>)RI645%1UYM[N_SL_.]S[9I EMMN3E;X5+51^X6BBBJ&%%%% !1110 4444 %%%% !1110!__V0$! end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 17, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 17, 2023
Entity File Number 001-41264
Entity Registrant Name Nuvectis Pharma, Inc.
Entity Central Index Key 0001875558
Entity Tax Identification Number 86-2405608
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1 Bridge Plaza Suite 275
Entity Address, City or Town Fort Lee
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07024
City Area Code 201
Local Phone Number 614-3150
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol NVCT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 8 tm2323981d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001875558 2023-08-17 2023-08-17 iso4217:USD shares iso4217:USD shares 0001875558 false 8-K 2023-08-17 Nuvectis Pharma, Inc. DE 001-41264 86-2405608 1 Bridge Plaza Suite 275 Fort Lee NJ 07024 201 614-3150 Common Stock NVCT NASDAQ false false false false true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nuvectis.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2323981d1_8k.htm nvct-20230817.xsd nvct-20230817_lab.xml nvct-20230817_pre.xml tm2323981d1_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2323981d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2323981d1_8k.htm" ] }, "labelLink": { "local": [ "nvct-20230817_lab.xml" ] }, "presentationLink": { "local": [ "nvct-20230817_pre.xml" ] }, "schema": { "local": [ "nvct-20230817.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "NVCT", "nsuri": "http://nuvectis.com/20230817", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323981d1_8k.htm", "contextRef": "AsOf2023-08-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://nuvectis.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323981d1_8k.htm", "contextRef": "AsOf2023-08-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nuvectis.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-092871-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-092871-xbrl.zip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end